Business Wire

London-based Tech Firm Unruly Set to Launch in Japan to Coincide with Mayor’s Trade Visit

Del

Unruly, the London based video ad tech company today announced it will open a new office in Tokyo as part of its global expansion plans, which coincides with a trip to Japan by Mayor of London, Boris Johnson MP.

The move marks the tech company’s continuing investment in the APAC region, following the opening of an office in Sydney, Australia in April and the launch of its APAC HQ in Singapore last year. Unruly was founded in London in 2006 and now employs 200 people across 15 offices with HQ operations in London, New York and Singapore.

The global video platform, which has worked with 90% of Ad Age 100 brands to help get their ads watched, tracked and shared online, is expanding its operations across APAC to help ROI-driven marketers in Japan benefit from its unique audience data, native video ad formats and mobile video exchange.

Japan has the third largest advertising market in the world, with research revealing that the online video market will be worth almost $1bn USD by 2017.

Over the next three days (October 13-15), The Mayor is leading a trade mission to Japan, where he will meet with senior Japanese politicians, business leaders and investors to foster closer ties and greater investment in life sciences, tech and innovation.

The visit is part of his continued drive to create jobs and growth in the capital by strengthening ties with world cities like Tokyo and promoting London to the world as a major investment destination.

He will be joined on the trip by London tech ambassador’s Eileen Burbidge MBE, HM Treasury FinTech Envoy and Derek White, Chief Innovation Officer, Barclays, to share London’s expertise and highlight the opportunities for technology innovation in Japan.

Mayor of London Boris Johnson MP said: “Unruly is one of the great success stories of London’s tech community and I’m delighted that the company is bringing their talent and innovation to the Japanese market. Japan is one of the world’s most important economic powerhouses and my visit is an opportunity to bang the drum for London and strengthen our ties with the country.”

Sarah Wood, Co-Founder and Co-CEO of Unruly said: "We are looking forward to bringing our unique data and insight to the Japanese market. Every market is different and Japan presents a huge opportunity for marketers looking to amplify the impact of their online video campaigns.

"Japan is still in the early stages of its digital video journey. Despite Japan currently having the third largest ad market in the world, only 3% of digital ad spend in 2014 was on online video. That’s going to change massively over the coming months, with some predicting that the Japanese online video market will be worth nearly $1bn USD by 2017.

"We want to be there from the outset to help develop the online ad industry in a way that is positive to publishers, brands and consumers."

Separately, the Mayor of London, Boris Johnson MP has today appointed Sarah Wood as a technology ambassador for London. She will join other ambassadors such as Russ Shaw, Founder of Tech London Advocates, Gerard Grech, CEO Tech City UK and Kathryn Parsons CEO Decoded, to help promote the capital’s tech sector on an international stage.

The Mayor of London continued: “Sarah is one of the most talented individuals working the tech sector. She has built a world-class business by harnessing the best of London’s talent and innovation and is already spreading the message of our tech sector to international investors and audiences. Sarah is a shining example of the dynamic, entrepreneurial spirit that’s so pervasive in London and she is an outstanding ambassador.”

Sarah Wood added: “It's a real honour to be asked to be a technology ambassador for London. London is the place to be if you want to start up and scale up a global technology company, and I want to make sure everyone around the globe is aware of all of the opportunities the capital offers. It's home to some of the most innovative companies in the world, we have more developers and investors than any other city in the world, there are highly favourable tax incentives for entrepreneurs and we have a vibrant, lively and diverse culture.”

Japan is the world’s third largest economy and was the fourth largest investor in London last year. Since 2003, Japan has invested close to £500 billion in almost 12,000 foreign projects, creating 2.6 million jobs around the world. In 2014, trade with the capital totalled almost £950million.

David Slater, Director of International Trade & Investment said: “As one of the world’s largest economies, Japan is an important trade and investment partner for London. From financial services firms to technology giants, London already serves as a key international hub for a number of leading Japanese businesses with a global footprint. We are also seeing a growing opportunity for fast growing London businesses such as Unruly to expand into the Japanese market. Japan offers London and UK businesses a perfect springboard into the rapidly developing APAC markets. We look forward to increased collaboration between the two countries, particularly when welcoming more ambitious Japanese businesses looking to establish a regional or global HQ in London.”

More foreign companies are expanding or setting up headquarters in London than ever before, with around 40% of the world’s top companies having a European or global HQ in London. London & Partners, the Mayor’s inward investment company, helped a record 270 companies set up or expand in the city last year, creating nearly 5,000 jobs.

-ENDS-

Notes to Editors:

About London & Partners.

London & Partners is the official promotional company for London. We promote London and attract businesses, events, congresses, students and visitors to the capital. Our aims are to build London’s international reputation and to attract investment and visitor spend, which create jobs and growth.

London & Partners is a not-for-profit public private partnership, funded by the Mayor of London and our network of commercial partners.

For more information visit www.londonandpartners.com

About Unruly

Unruly is the ad tech company that gets videos watched, tracked and shared across the Open Web. Positioned at the intersect of video, social, native & mobile, Unruly uses emotional audience data and user-friendly video formats to massively increase viewer engagement, brand performance & publisher revenues. With 3 out of every 4 video views now taking place outside of YouTube, 90% of Ad Age 100 brands have already used Unruly to connect with audiences at speed and scale across the Open Web.

Differentiated by a unique data set of 2 trillion video views and powered by a full tech stack, Unruly adds value by algorithmically evaluating content shareability and programmatically targeting custom audiences. Viewability is 100% guaranteed to an audience of 1.35 billion monthly unique users across mobile, tablet and desktop devices. UnrulyX is the first supply side platform (SSP) for mobile video to offer scaled delivery of native ad formats and guarantee the viewability of premium video impressions bought via RTB.

Unruly employs 200 people across 15 offices, with regional HQs in London, New York and Singapore. Its super power is emotional ad tech. Its secret weapon is passionate people on a mission to #DeliverWow. Unruly was acquired by News Corp in September 2015.

Contact information

Ben Pattie, PR Manager FDI & Tech
Tel: +44 (0)20 7234 5872/+44 (0)7879224349
bpattie@londonandpartners.com
or
London & Partners Media & PR Team
Tel: +44 (0)20 7234 5710
Switch: +44 (0)20 7234 5800
press@londonandpartners.com
Twitter: @London_PR

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19Pressemelding

Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom